Tradename | Company | Number | Date | Products |
---|---|---|---|---|
GLUCAGON | Fresenius Kabi | N-201849 RX | 2015-05-08 | 2 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
BAQSIMI | Amphastar Pharmaceuticals | N-210134 RX | 2019-07-24 | 1 products, RLD, RS |
GVOKE PFS | Xeris Pharmaceuticals | N-212097 RX | 2019-09-10 | 1 products, RLD, RS |
GVOKE HYPOPEN | Xeris Pharmaceuticals | N-212097 RX | 2019-09-10 | 2 products, RLD, RS |
GVOKE KIT | Xeris Pharmaceuticals | N-212097 RX | 2021-08-20 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
baqsimi | New Drug Application | 2024-11-13 |
glucag0n | New Drug Application | 2022-12-09 |
glucagen 10-pack glucagen diagnostic kit glucagen hypokit | 2008-08-21 | |
glucagen hypokit | New Drug Application | 2021-03-19 |
glucagon | New Drug Application | 2024-02-22 |
glucagon glucagon | New Drug Application | 2019-05-22 |
gvoke hypopen gvoke kit gvoke pfs | New Drug Application | 2023-01-10 |
gvoke hypopen gvoke pfs | New Drug Application | 2021-07-15 |
gvoke hypopen gvoke kit gvoke pfs | New Drug Application | 2025-03-26 |
gvoke hypopen gvoke pfs | New Drug Application | 2019-09-10 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 27 | 20 | 62 | 13 | 12 | 129 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 20 | 19 | 64 | 10 | 9 | 117 |
Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 3 | 1 | 2 | 1 | 8 |
Fatty liver | D005234 | EFO_0003934 | — | — | 1 | — | 1 | — | 2 |
Body weight | D001835 | EFO_0004338 | — | — | 1 | — | 1 | — | 2 |
Weight gain | D015430 | — | — | — | — | 1 | 1 | — | 2 |
Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | — | 2 | — | 2 |
Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | — | — | 1 | — | 1 |
Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | — | 1 | — | 1 |
Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypoglycemia | D007003 | — | E16.2 | 2 | 2 | 4 | — | — | 7 |
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 5 | 1 | 2 | — | — | 7 |
Overweight | D050177 | — | E66.3 | 1 | 2 | 1 | — | — | 4 |
Hyperglycemia | D006943 | — | R73.9 | 1 | 3 | 2 | — | — | 3 |
Glucose metabolism disorders | D044882 | — | — | — | — | 2 | — | — | 2 |
Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | — | 2 | — | — | 2 |
Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | 2 | — | — | 2 |
Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | — | 2 | — | — | 2 |
Weight loss | D015431 | — | — | — | — | 1 | — | 1 | 2 |
Chronic renal insufficiency | D051436 | — | N18 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | 1 | — | — | — | 1 |
Diabetes complications | D048909 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 12 | — | — | — | 1 | 13 |
Common cold | D003139 | EFO_0007214 | J00 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Carcinoma | D002277 | — | C80.0 | — | — | — | — | 1 | 1 |
Thyroid neoplasms | D013964 | EFO_0003841 | — | — | — | — | — | 1 | 1 |
Neuroendocrine carcinoma | D018278 | — | — | — | — | — | — | 1 | 1 |
Papillary thyroid cancer | D000077273 | — | — | — | — | — | — | 1 | 1 |
Thyroid diseases | D013959 | — | E00-E07 | — | — | — | — | 1 | 1 |
Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | — | — | 1 | 1 |
Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
Pancreatitis | D010195 | EFO_0000278 | K85 | — | — | — | — | 1 | 1 |
Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | — | — | — | — | 1 | 1 |
Peripheral nervous system diseases | D010523 | — | G64 | — | — | — | — | 1 | 1 |
Drug common name | Glucagon |
INN | glucagon |
Description | Glucagon is a 29-amino acid peptide hormone consisting of His, Ser, Gln, Gly, Thr, Phe, Thr, Ser, Asp, Tyr, Ser, Lys, Tyr, Leu, Asp, Ser, Arg, Arg, Ala, Gln, Asp, Phe, Val, Gln, Trp, Leu, Met, Asn and Thr residues joined in sequence. |
Classification | Protein |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O |
PDB | — |
CAS-ID | 9007-92-5 |
RxCUI | — |
ChEMBL ID | CHEMBL266481 |
ChEBI ID | 5391 |
PubChem CID | 16132283 |
DrugBank | DB00040 |
UNII ID | 76LA80IG2G (ChemIDplus, GSRS) |